193 related articles for article (PubMed ID: 23708655)
1. HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.
Calero-Nieto FJ; Joshi A; Bonadies N; Kinston S; Chan WI; Gudgin E; Pridans C; Landry JR; Kikuchi J; Huntly BJ; Gottgens B
Oncogene; 2013 Nov; 32(48):5471-80. PubMed ID: 23708655
[TBL] [Abstract][Full Text] [Related]
2. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
3. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
[TBL] [Abstract][Full Text] [Related]
4. The LMO2 -25 Region Harbours GATA2-Dependent Myeloid Enhancer and RUNX-Dependent T-Lymphoid Repressor Activity.
Bonadies N; Göttgens B; Calero-Nieto FJ
PLoS One; 2015; 10(7):e0131577. PubMed ID: 26161748
[TBL] [Abstract][Full Text] [Related]
5. LMO2 is required for TAL1 DNA binding activity and initiation of definitive haematopoiesis at the haemangioblast stage.
Stanulovic VS; Cauchy P; Assi SA; Hoogenkamp M
Nucleic Acids Res; 2017 Sep; 45(17):9874-9888. PubMed ID: 28973433
[TBL] [Abstract][Full Text] [Related]
6. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
[TBL] [Abstract][Full Text] [Related]
7. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis.
Wu C; Li J; Tian C; Shi W; Jiang H; Zhang Z; Wang H; Zhang Q; Sun W; Sun P; Xiang R; Yang S
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2511-2525. PubMed ID: 29778661
[TBL] [Abstract][Full Text] [Related]
9. High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.
Wu L; Xu Y; Wang Q; Ruan C; Drexler HG; Wu D; MacLeod RA; Chen S
Haematologica; 2015 Jun; 100(6):e233-6. PubMed ID: 25682596
[No Abstract] [Full Text] [Related]
10. Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
Shields BJ; Alserihi R; Nasa C; Bogue C; Alexander WS; McCormack MP
Leukemia; 2015 Apr; 29(4):927-38. PubMed ID: 25283843
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
12. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
[TBL] [Abstract][Full Text] [Related]
13. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.
Goossens S; Wang J; Tremblay CS; De Medts J; T'Sas S; Nguyen T; Saw J; Haigh K; Curtis DJ; Van Vlierberghe P; Berx G; Taghon T; Haigh JJ
Haematologica; 2019 Aug; 104(8):1608-1616. PubMed ID: 30679322
[TBL] [Abstract][Full Text] [Related]
14. Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.
Landry JR; Bonadies N; Kinston S; Knezevic K; Wilson NK; Oram SH; Janes M; Piltz S; Hammett M; Carter J; Hamilton T; Donaldson IJ; Lacaud G; Frampton J; Follows G; Kouskoff V; Göttgens B
Blood; 2009 Jun; 113(23):5783-92. PubMed ID: 19171877
[TBL] [Abstract][Full Text] [Related]
15. Activation of the
Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
[TBL] [Abstract][Full Text] [Related]
16. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.
McCormack MP; Young LF; Vasudevan S; de Graaf CA; Codrington R; Rabbitts TH; Jane SM; Curtis DJ
Science; 2010 Feb; 327(5967):879-83. PubMed ID: 20093438
[TBL] [Abstract][Full Text] [Related]
17. Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.
Deleuze V; El-Hajj R; Chalhoub E; Dohet C; Pinet V; Couttet P; Mathieu D
PLoS One; 2012; 7(7):e40484. PubMed ID: 22792348
[TBL] [Abstract][Full Text] [Related]
18. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
[TBL] [Abstract][Full Text] [Related]
19. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.
Homminga I; Vuerhard MJ; Langerak AW; Buijs-Gladdines J; Pieters R; Meijerink JP
Haematologica; 2012 Feb; 97(2):258-61. PubMed ID: 22058201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
